Associated Papers
A multiplex, prime editing framework for identifying drug resistance variants at scale.
Abadie FMC et al.
Cell Genomics, 2026
TP53 Functional-Domain-Specific Mutations Define Distinct Clinical Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
Kobayashi K
Journal of Clinical Medicine, 2026
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Targeted Protein Degradation Strategies for Lung Cancers: Focusing on Epidermal Growth Factor Receptor.
Hou M et al.
Chemistry & Biodiversity, 2026
Common gene mutations in 103 authenticated colorectal cancer cell lines.
Kranjec C et al.
Oncogenesis, 2026
Mutational landscape of lung adenocarcinoma in Czechia.
Ambrozkiewicz F et al.
Cancer Treatment and Research Communications, 2026
Efficacy of TKIs in non-small cell lung cancer with atypical EGFR p.L747P and p.L747S mutations.
Hu Q et al.
Frontiers in Oncology, 2026
A fuzzy sequencer for rapid DNA fragment counting and genotyping.
Zhou W et al.
Nature Biomedical Engineering, 2025
Challenges associated with the treatment of E709K and L858R double mutation in lung adenocarcinoma: A case report and literature review.
Song J et al.
Oncology Letters, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Endotracheal and Endobronchial Metastases in Epidermal Growth Factor Receptor Exon 19 Deletion Lung Adenocarcinoma: A Case Successfully Managed with Bronchoscopic Therapy and Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Fujiwara M et al.
Internal Medicine (tokyo, Japan), 2025
Mismatch-introduced crRNA guided PCR-CRISPR/Cas12a platform improves EGFR point mutation detection in single tumor cell.
Wu M et al.
Mikrochimica Acta, 2025
Genetic Alteration Profiling in North Macedonian Lung Cancer Patients.
Eftimov A et al.
Genes, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer: A Real-World Cohort Study in Finland.
Hormalainen K et al.
Cancer Medicine, 2025
Clinical Outcomes of Later-Generation EGFR-TKIs for Uncommon EGFR Mutations in NSCLC: A Multicenter Real-World Study.
Shigematsu L et al.
Thoracic Cancer, 2025
The characteristics and prognoses of 72 postoperative synchronous multiple primary lung cancer patients.
Yang Y et al.
World Journal of Surgical Oncology, 2025
Actionable mutations and targeted therapy in non-small cell lung cancer among Latin American and Hispanic patients: a systematic literature review of prognosis and meta-analysis.
Castañeda-González JP et al.
Translational Lung Cancer Research, 2025
Oncogenic driver mutations underlie the spatial tumour immune landscape of non-small cell lung cancer.
Hartner S et al.
Nature Communications, 2025
[Expert consensus on the diagnosis and treatment of advanced non-small cell lung cancer with EGFR PACC mutations (2025 edition)].
Unknown Author
Zhonghua Zhong Liu Za Zhi [chinese Journal of Oncology], 2025
Current paradigm of EGFRins20 in non-small cell lung cancer: A long way forward.
Miyamura BV et al.
Med (new York, N.y.), 2025
Multimodal scanning of genetic variants with base and prime editing.
Belli O et al.
Nature Biotechnology, 2025
Saturation profiling of drug-resistant genetic variants using prime editing.
Kim Y et al.
Nature Biotechnology, 2025
Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial.
Park S et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2025
Phase II study of afatinib for advanced non-small cell lung cancer with uncommon epidermal growth factor receptor mutations, including compound mutations detected by next-generation sequencing.
Mamesaya N et al.
International Journal of Clinical Oncology, 2025
Rare mutations at EGFR L747 position: molecular characteristics and superior response to afatinib in NSCLC patients.
Huang Y et al.
Esmo Open, 2025
Concurrent EGFR L858R and K860I mutations: PCR-negative but NGS-positive alterations that respond to EGFR inhibitors in non-small cell lung cancer.
Shi H et al.
Journal of Thoracic Disease, 2025
Alignment-free unique molecular identifier clustering suppresses sequencing errors for accurate detection of low-frequency DNA variants.
Yu F et al.
Briefings in Bioinformatics, 2025
Genetic mechanisms of resistance to targeted KRAS inhibition.
Diaz BJ et al.
Biorxiv : the Preprint Server for Biology, 2025
On-target toxicity limits the efficacy of CDK11 inhibition against cancers with 1p36 deletions.
Julian L et al.
Biorxiv : the Preprint Server for Biology, 2025
Rare sequential EGFR and ALK mutations in non-small cell lung cancer: A case report and literature review.
Nguyen HV et al.
Oncology Letters, 2025
Spectrum of rare EGFR mutations in Indonesian lung adenocarcinoma: Findings from an 8-year analysis of 4,778 cases highlighting the need for advanced targeted therapies.
Heriyanto DS et al.
Narra J, 2025
STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models.
Pagliarini RA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Dr. Kinase: predicting the drug-resistance hotspots of protein kinases.
Lin S et al.
Nucleic Acids Research, 2025
An in-depth exploration of four heterogeneity structure-based EGFR mutation subgroups in Chinese non-small cell lung cancer.
Yu Y et al.
Bmc Pulmonary Medicine, 2025
A targeted next-generation sequencing panel for identification of clinically relevant mutation profiles in solid tumours.
Das K et al.
Scientific Reports, 2025
Lysosomal EGFR acts as a Rheb-GEF independent of its kinase activity to activate mTORC1.
He X et al.
Cell Research, 2025
Assessing mutation-clinical correlations and treatment outcomes in Vietnamese non-small cell lung cancer patients.
Nguyen HB et al.
Practical Laboratory Medicine, 2025
The Prevalence, Distribution, and Clinicopathological Features of Seven Lung Cancer Actionable Driver Mutations in Taiwan.
Lin YC et al.
Thoracic Cancer, 2025
Good responses to first-line immunotherapy-included treatment in lung squamous carcinoma with rare driver gene mutations: a report of three cases.
Tu L et al.
Translational Lung Cancer Research, 2025
Comprehensive Evaluation of a 1021-Gene Panel in FFPE and Liquid Biopsy for Analytical and Clinical Use.
Meintani A et al.
International Journal of Molecular Sciences, 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patients.
van der Leest P et al.
Communications Medicine, 2025